A patient with Fechtner syndrome successfully treated with romiplostim

• References

• 1 Peterson LC, Rao KV, Crosson JT. et al. Fechtner syndrome--a variant of alport's syndrome with leukocyte inclusions and macrothrombocytopenia. Blood 1985; 65: 397-406.
• 2 Kunishima S, Matsushita T, Kojima T. et al. Identification of six novel myh9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions. J Hum Genet 2001; 46: 722-729.
• 3 Seri M, Cusano R, Gangarossa S. et al. Mutations in myh9 result in the may-hegglin anomaly, and fechtner and sebastian syndromes. The may-heggllin/ fechtner syndrome consortium. Nat Genet 2000; 26: 103-105.
• 4 Pecci A, Gresele P, Klersy C. et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from myh9 mutations. Blood 2010; 116: 5832-5837.
• 5 Savoia A, De Rocco D, Panza E. et al. Heavy chain myosin 9-related disease (myh9 -rd): Neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost 2010; 103: 826-832.
• 6 Kuter DJ, Mufti GJ, Bain BJ. et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009; 114: 3748-3756.
• 7 Kantarjian H, Fenaux P, Sekeres MA. et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010; 28: 437-444.